NANTES, France I June 2, 2025 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today provided clinical updates on Tedopi®, the “off-the-shelf” neo-epitope-based therapeutic cancer vaccine under evaluation in both monotherapy and combination therapy across five clinical trials in several cancer indications. Silvia Comis, MD, Chief Clinical and Medical Research Officer OSE Immunotherapeutics , commented: “We are pleased to share the latest clinical updates on our cancer vaccine Tedopi

Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; Olmsted syndrome, severe keratoderma and ichthyosis Company plans to commence and report top-line results from a Phase 1b clinical trial of KM023 for the treatment of Olmstead syndrome by year-end 2025 NESS ZIONA, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Kamari Pharma, a pri

Top 25 Global Life Science Organization Adopts NavaX, Demonstrating Industry Confidence in Scalable, GenAI-Enabled Technologies BOSTON, June 3, 2025 /PRNewswire/ -- ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced that another Top 25 global pharmaceutical company has selected LifeSphere NavaX, the next-generation cognitive computing engine, to enhance case processing and pharmacovigilance operations. This milestone marks t

- One-year follow-up data from first-in-human trial shows significant improvements in key clinical performance outcomes - This data supports a strong safety profile for the VCFix® Spinal System for the treatment of vertebral compression fractures THE HAGUE, Netherlands, June 3, 2025 /PRNewswire/ -- Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announces the completion of the one-year follow-up for all patients enrolled in

Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technologyLehi, June 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah – June 3rd, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform that will use the body’s immune system to fight cancer, today announced that two of its lead scientists, Dr. George Katibah and Dr. Adam Grant, were recently featured on Cytiva’s influential podcast series, Discovery Matter

SINGAPORE I June 3, 2025 I The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showe

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1First Phase III study in ES-SCLC first-line maintenance to demonstrate clinically meaningful improvements in both progression-free and overall survival 2,3 Data were presented in an oral session at the 2025 ASCO Annual Meeting and simultaneously published in The Lancet 1,4 Basel, 3 June 2025 - Roche (SIX: RO, ROG; OTCQX

Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder regulatory review in the US, the EU, and China in immune thrombocytopenia Paris, June 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlu

Having inked a multi-billion-dollar deal with Bristol Myers Squibb for its PD-L1/VEGF-A bispecific antibody on Monday, BioNTech's presentation Tuesday on the efficacy of BNT327 in treating mesothelioma at the American Society of Clinical Oncology (ASCO) meeting was just the cherry on top.  BMS shelled out $1.5 million upfront to co-develop BNT327 with BioNTech, as excitement for PD-(L)1/VEGF bispecifics shows no signs of diminishing; Merck & Co. and Pfizer paid $588 million and $1.25 billion upf

PharmaEssentia’s Besremi (ropeginterferon alfa-2b) showed superior efficacy and safety compared with Takeda’s platelet-reducing drug Agrylin/Xagrid (anagrelide) as second-line therapy for essential thrombocythaemia (ET) in a Phase III study. The detailed results fom the SURPASS-ET trial which top-lined in January were presented at the American Society of Clinical Oncology (ASCO) annual meeting on Monday.The study enrolled 174 patients who were randomised to receive either Besremi or Agrylin/Xagr